ARWR vs ESS · rev $829.4M vs P/E 31, rev $489.0M
Arrowhead Pharmaceuticals Inc (ARWR) versus Essex Property Trust Inc (ESS) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
Essex Property Trust Inc (ESS) is a reit - residential company listed on NYSE.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported ESS revenue for 2026-06-30 was $489.0M. Net income was $66.9M. Revenue was up 0.9% from 2026-03-31 to 2026-06-30. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
ARWR currently screens at market cap $10.59B. ESS currently screens at market cap $18.91B and trailing P/E 30.9.
Not investment advice. Open the ARWR and ESS stock pages for the full models.
Not investment advice.